Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regional Bioavailability of ABT-333 in Healthy Subjects
NCT02052349Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc. Primary endpoint: ABT-333 drug concentrations. Started Nov 2013; status: completed.
02
Drugs
dasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02052349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052349.